Tennessee Oncology

Running trials

• Recruiting

  A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT07719361· Phase 1· Source

• Recruiting

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· Phase 2/3· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Source

• Recruiting

  A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  NCT07629960· Phase 1/2· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Source

• Recruiting

  Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

  NCT06930755· Phase 1· Source

• Recruiting

  Horizon Two: HR NDMM (MMRC-100)

  NCT07053436· Phase 2· Source

• Recruiting

  A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

  NCT07469891· Phase 1· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· Source

• Recruiting

  A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

  NCT07544589· Phase 1· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  NCT07291076· Phase 1/2· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Source

• Recruiting

  A Study of BI 3810944 in Patients With Advanced Cancer

  NCT07224425· Phase 1· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Source

• Active, not recruiting

  A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07266441· Phase 2· Source

• Recruiting

  A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

  NCT07287995· Phase 1/2· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  NCT07397338· Phase 1/2· Source

• Recruiting

  This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

  NCT07121946· Phase 1· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Source

• Recruiting

  A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  NCT07361562· Phase 1· Source

• Recruiting

  Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  NCT07288359· Phase 1/2· Source

• Recruiting

  A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

  NCT07221474· Phase 2· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  NCT07100080· Phase 2/3· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Source

• Recruiting

  A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  NCT07005154· Phase 2· Source

• Recruiting

  Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

  NCT06931626· Phase 1· Source

• Recruiting

  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· Phase 3· Source

• Active, not recruiting

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· Phase 2· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Source

• Recruiting

  A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  NCT06876649· Phase 4· Source

• Recruiting

  A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  NCT06876662· Phase 4· Source

• Recruiting

  A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

  NCT06926920· Phase 1/2· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Source

• Active, not recruiting

  A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06356571· Phase 2· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Source

• Recruiting

  Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer28 recruiting
• Prostate cancer16 recruiting
• Bladder cancer13 recruiting
• Multiple myeloma13 recruiting
• Triple-negative breast cancer11 recruiting
• Colorectal cancer9 recruiting
• Kidney cancer9 recruiting
• Melanoma9 recruiting
• Chronic lymphocytic leukaemia7 recruiting
• Metastatic breast cancer7 recruiting
• Ovarian cancer7 recruiting
• Gastric and esophageal cancer6 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Follicular lymphoma5 recruiting
• Head and neck cancer5 recruiting
• Pancreatic cancer5 recruiting
• Cervical cancer4 recruiting
• Endometrial cancer4 recruiting
• Mantle cell lymphoma4 recruiting
• Hodgkin lymphoma3 recruiting
• Liver and biliary tract cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Childhood cancers2 recruiting
• Mesothelioma2 recruiting
• Sarcoma2 recruiting
• Acute myeloid leukemia1 recruiting
• Glioblastoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

  NCT05948462· Phase 2· Source

• Terminated

  Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

  NCT05908396· Phase 1· Source

• Recruiting

  A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  NCT05780034· Phase 1· Source

• Completed

  First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

  NCT05759949· Phase 1· Source

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Phase 1· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Source

• Completed

  A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

  NCT05538572· Phase 1· Source

• Completed

  Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

  NCT05585034· Phase 1· Source

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Source

• Withdrawn

  To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

  NCT05212701· Phase 2· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Phase 1· Source

• Terminated

  Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

  NCT05357898· Phase 1/2· Source

• Terminated

  A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

  NCT05121948· Phase 1· Source

• Completed

  Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

  NCT05054725· Phase 2· Source

• Completed

  Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

  NCT05199337· Phase 1/2· Source

• Terminated

  NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

  NCT04984811· Phase 2· Source

• Completed

  FT576 in Subjects With Multiple Myeloma

  NCT05182073· Phase 1· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Source

• Completed

  Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

  NCT05041257· Phase 2· Source

• Completed

  AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

  NCT04885998· Phase 1· Source

• Completed

  A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

  NCT05039177· Phase 1/2· Source

• Terminated

  A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

  NCT04982926· Phase 1· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

  NCT04956692· Phase 3· Source

• Completed

  177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Phase 3· Source

• Recruiting

  A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

  NCT04872166· Phase 1· Source

• Terminated

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

  NCT04887831· Phase 2· Source

• Completed

  XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

  NCT04825288· Phase 1/2· Source

• Terminated

  Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

  NCT04795713· Phase 1· Source

• Completed

  A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

  NCT04752215· Phase 1· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· Source

• Completed

  A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

  NCT04699630· Phase 2· Source

• Terminated

  A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

  NCT04740034· Phase 1· Source

• Completed

  Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

  NCT04774952· Phase 1· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Source

• Completed

  A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

  NCT04665843· Phase 2· Source

• Recruiting

  A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04634552· Phase 2· Source

• Completed

  Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

  NCT04463771· Phase 2· Source

• Completed

  Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

  NCT04488354· Phase 1· Source

• Terminated

  A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

  NCT04543188· Phase 1· Source

• Completed

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· Phase 2· Source

• Recruiting

  Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

  NCT04683250· Phase 1/2· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Source

• Completed

  LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

  NCT04666688· Phase 1/2· Source

• Completed

  A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

  NCT04670679· Phase 1· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

  NCT04619797· Phase 2/3· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Completed

  Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

  NCT04631445· Source

Trial sites

• Tennessee Oncology8 trials
• Tennessee Oncology Hendersonville1 trial
• Tennessee Oncology, PLLC3 trials
• Tennessee Oncology, PLLC,353 New Shackle Island Road2 trials
• Tennessee Oncology, PLLC - Hendersonville2 trials
• Tennessee Oncology, PLLC7 trials
• Tennessee Oncology, PLLC,5653 First Blvd.2 trials
• Tennessee Oncology - SUMMIT - SCRI - PPDS1 trial
• Tennessee Oncology, PLLC - Mount Juliet4 trials
• Duplicate_SCRI - Tennessee Oncology /ID# 2699211 trial
• One Oncology - Tennessee Oncology (Site 0098)1 trial
• One Oncology - Tennessee Oncology (Site 4019)1 trial
• Sarah Cannon Research Institute (Tennessee Oncology)24 trials
• Sarah Cannon Research Institute - Tennessee Oncology, PLLC1 trial
• Sarah Cannon - Tennessee Oncology7 trials
• Sarah Cannon (Tennessee Oncology - Nashville)4 trials
• SCRI - Tennessee Oncology7 trials
• SCRI - Tennessee Oncology - Nashville - Centennial2 trials
• Tennessee Oncology112 trials
• Tennessee Oncology (0036)1 trial
• Tennessee Oncology, Greco-Hainsworth Center for Research1 trial
• Tennessee Oncology - Midtown1 trial
• Tennessee Oncology - Nashville14 trials
• Tennessee Oncology Nashville /ID# 2690291 trial
• Tennessee Oncology - Nashville - Midtown Center for Blood Cancers1 trial
• Tennessee Oncology Nashville (Site 0004)1 trial
• Tennessee Oncology Nashville- Site Number : 84000121 trial
• Tennessee Oncology, PLLC58 trials
• Tennessee Oncology, PLLC,2004 Hayes Street2 trials
• Tennessee Oncology, PLLC,3443 Dickerson Road2 trials
• Tennessee Oncology, PLLC,397 Wallace Road2 trials
• Tennessee Oncology, PLLC,4220 Harding Rd2 trials
• Tennessee Oncology, PLLC- Elliston Place Plaza1 trial
• Tennessee Oncology, PLLC - Elliston Place Plaza DDU1 trial
• Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology3 trials
• Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology (Site 0031)1 trial
• Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology (Site 0831)1 trial
• Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology (Site 9000)1 trial
• Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research2 trials
• Tennessee Oncology, PLLC /ID# 2071751 trial
• Tennessee Oncology, PLLC /ID# 2153261 trial
• Tennessee Oncology, PLLC /ID# 2462831 trial
• Tennessee Oncology, PLLC - Investigational Drug Services6 trials
• Tennessee Oncology, Pllc Nashville5 trials
• Tennessee Oncology, PLLC-Nashville-525681 trial
• Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers1 trial
• Tennessee Oncology, PLLC - Nashville Elliston Place Plaza DDU1 trial
• Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology1 trial
• Tennessee Oncology, PLLC - Nashville Saint Thomas West2 trials
• Tennessee Oncology, PLLC - Nashville Skyline1 trial
• Tennessee Oncology, PLLC - Nashville Southern Hills1 trial
• Tennessee Oncology, PLLC - Saint Thomas West3 trials
• Tennessee Oncology, PLLC,SCRI Oncology Partners2 trials
• Tennessee Oncology, PLLC (Site 0001)1 trial
• Tennessee Oncology, PLLC (Site 0020)1 trial
• Tennessee Oncology, PLLC- Skyline2 trials
• Tennessee Oncology, PLLC- Southern Hills2 trials
• Tennessee Oncology (Sarah Cannon)1 trial
• Tennessee Oncology - Sarah Cannon Research Institute6 trials
• Tennessee Oncology/SCRI3 trials
• Tennessee Oncology (Site 0018)1 trial
• Tennessee Oncology (Site 0051)1 trial
• Tennessee Oncology (Site 0068)1 trial
• Tennessee Oncology (Site 0111)1 trial
• Tennessee Oncology Site Number : 84000061 trial
• Tennessee Oncology - Skyline Satellite1 trial
• Tennessee Oncology - SOUTHERN HILLS - SCRI - PPDS1 trial
• Tennessee Oncology - ST THOMAS WEST - SCRI - PPDS1 trial
• The Sarah Cannon Research Institute/Tennessee Oncology4 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Mantle cell lymphoma5 works · 12 trials